Please login to the form below

Not currently logged in
Email:
Password:

Former Merck & Co exec to lead Seres

Roger Pomerantz was senior VP at pharma giant

Roger Pomerantz MerckSeres has appointed Dr Roger Pomerantz, formerly a senior figure at Merck & Co, to lead the company as CEO and chairman.

Dr Pomerantz was senior VP and worldwide head of licensing and acquisitions at Merck & Co, overseeing all licensing and acquisition activities at the company. This included external research and academic alliances.

He will now lead a company making advances in treat infectious diseases, with Seres' lead candidate a potential treatment for clostridium difficile (C. difficile).

Dr Pomerantz has considerable experience in the area of infectious diseases, serving as global franchise head of infectious diseases at Merck immediately prior to his role in licensing and acquisitions. 

Previously he was global head of infectious diseases for Johnson & Johnson having joined the company as president of its Tiobtec Pharmacueticals division, now known as Janssen Therapeutics.

In total Dr Pomerantz has been involved with the development of eight approved drugs for infectious diseases, covering HIV, hepatitis C and tuberculosis.

"With our lead product currently in clinical testing for the treatment of recurrent C. difficile, and a rapidly growing pipeline, Roger's expertise is ideally suited to provide the leadership that can execute on Seres' pioneering vision,” said Dr Noubar Afeyan, co-founder of Seres.

9th June 2014

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics